| Antigen-binding polypeptide constructs comprising kappa and lambda light chains … |
2023-8-10 |
2023-8-31 |
|
| Immunomodulatory trispecific t cell engager fusion proteins |
2023-1-26 |
2023-8-03 |
|
| Methods of using anti-her2 biparatopic antibody-drug conjugates in the … |
2023-1-26 |
2023-8-03 |
|
| Modified antigen binding polypeptide constructs and uses thereof |
2022-11-22 |
2023-3-01 |
|
| Sulfonamide-containing linkage systems for drug conjugates |
2022-11-18 |
2023-8-24 |
|
| Systems and methods for polymer sequence prediction |
2022-11-01 |
2023-5-04 |
|
| Systems and methods for polymer side-chain conformation prediction |
2022-11-01 |
2023-5-04 |
|
| Modified interleukin p40 subunit proteins and methods of use thereof |
2022-9-29 |
2023-4-06 |
|
| Methods of treating cancer with anti-her2 biparatopic antibodies |
2022-9-15 |
2023-3-15 |
|
| Methods of treating cancer with anti-her2 biparatopic antibodies |
2022-9-15 |
2023-3-23 |
|
| Multivalent polypeptide constructs capable of binding viral spike proteins and … |
2022-9-14 |
2023-3-17 |
|
| Fc variant with high thermal stability and attenuated effector function |
2022-9-02 |
2023-3-03 |
|
| Fc variant with high thermal stability and attenuated effector function |
2022-9-02 |
2023-3-09 |
|
| Camptothecin analogues, conjugates and methods of use |
2022-5-27 |
2022-12-01 |
|
| Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
2022-5-25 |
2022-8-09 |
|
| Bispecific antigen binding constructs targeting her2 |
2022-4-25 |
2023-4-20 |
|
| Modified extracellular domain of granulocyte colony-stimulating factor receptor … |
2022-4-03 |
2022-6-01 |
|
| Cysteine engineered antibody constructs, conjugates and methods of use |
2022-3-25 |
2022-9-29 |
|
| Modified antigen binding polypeptide constructs and uses thereof |
2022-2-25 |
2022-8-11 |
|
| CONJUGATES OF ANTIBODIES AND ANTI-TISSUE FACTOR DRUGS AND RELATED METHODS |
2022-2-01 |
2022-5-31 |
|
| Stabilized tcr constructs and methods of use |
2021-12-21 |
2022-6-30 |
|
| Methods of using a bispecific antigen-binding construct targeting her2 for the … |
2021-12-14 |
2022-1-17 |
|
| Imidazothienopyridine compounds and methods of use |
2021-12-14 |
2022-6-23 |
|
| Heterodimeric iga fc constructs and methods of use thereof |
2021-12-03 |
2022-6-09 |
|
| Cytotoxic and anti-mitotic compounds, and methods of using the same |
2021-10-27 |
2021-12-01 |
|
| Anti-pd-1/lag3 bispecific antibodies |
2021-7-23 |
2021-12-02 |
|
| Fusion proteins comprising a ligand-receptor pair and a biologically functional … |
2021-7-20 |
2023-2-02 |
|
| Engineered Immunoglobulin Heavy Chain-Light Chain Pairs and Uses Thereof |
2021-6-09 |
2021-10-07 |
|
| Heterodimeric fc variants selective for fc gamma riib |
2021-5-20 |
2021-11-25 |
|
| Immunoglobulin fc region variants comprising stability-enhancing mutations |
2021-5-20 |
2021-11-25 |
|
| Antigen-Binding Constructs Targeting HER2 |
2021-5-03 |
2021-12-23 |
|
| Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof |
2021-4-09 |
2023-2-22 |
|
| Antibody constructs binding 4-1bb and tumor-associated antigens and uses … |
2021-4-09 |
2023-2-16 |
|
| Masked IL12 fusion proteins and methods of use thereof |
2021-3-23 |
2022-12-27 |
|
| Anti-her2 biparatopic antibody-drug conjugates and methods of use |
2021-3-23 |
2021-11-11 |
|
| Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs |
2021-3-19 |
2021-10-14 |
|
| Methods using monovalent antigen binding constructs targeting her2 |
2020-12-17 |
2021-9-02 |
|
| STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAIN |
2020-11-30 |
2021-9-09 |
|
| Methods of using bispecific antigen-binding constructs targeting her2 |
2020-9-25 |
2021-6-24 |
|
| Multivalent heteromultimer scaffold design and constructs |
2020-6-10 |
2021-1-14 |
|
| Methods of using a bispecific antigen-binding construct targeting her2 in … |
2020-5-29 |
2021-6-10 |
|
| Checkpoint inhibitor bispecific antibodies |
2020-1-09 |
2020-11-09 |
|
| 4-1BB BINDING ANTIBODY CONSTRUCTS AND TUMOR-ASSOCIATED ANTIGENS AND USES … |
2019-10-10 |
2021-9-21 |
|
| BI-SPECIFIC ANTIBODIES ANTI-PD-L1-ANTI-TIM-3 |
2019-10-10 |
2019-10-31 |
|
| STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAIN |
2019-9-12 |
2020-3-19 |
|
| Multivalent heteromultimer scaffold design and constructs |
2019-5-21 |
2022-2-15 |
2022-2-15 |
| ANTI-HER2 DRUG-BIPARATOPIC ANTIBODY CONJUGATES AND METHODS OF USE |
2019-3-13 |
2020-9-09 |
|
| Cytotoxic and anti-mitotic compounds, and methods of using the same |
2019-2-11 |
2023-4-04 |
2023-4-04 |
| Systems and methods for variable fitting on the basis of manual review |
2018-7-16 |
2019-2-14 |
|
| Stabilized chimeric fabs |
2018-6-29 |
2019-12-12 |
|
| Anti-gprc5d antibody and molecule containing same |
2018-6-02 |
2019-12-05 |
|
| Tumor antigen presentation inducer constructs and uses thereof |
2018-3-29 |
2018-10-04 |
|
| Systems and methods for making two dimensional graphs of complex molecules |
2017-11-21 |
2019-4-09 |
2019-4-09 |
| Compositions and methods for the treatment of platinum-drug resistant cancer |
2017-10-04 |
2018-7-12 |
|
| Methods of using bispecific antigen-binding constructs targeting her2 |
2017-4-25 |
2020-9-24 |
|
| Target the polyspecific antigen-binding constructs of immunotherapeutic agent |
2017-4-13 |
2019-1-04 |
|
| Antibodies having enhanced or suppressed effector functions |
2017-3-13 |
2017-9-21 |
|
| Process and methods for efficient manufacturing of highly pure asymmetric … |
2016-11-17 |
2017-6-08 |
|
| Single-Arm Monovalent Antibody Constructs and Uses Thereof |
2016-10-20 |
2017-6-22 |
|
| Compositions and methods for the treatment of platinum-drug resistant cancer |
2016-10-04 |
2018-4-04 |
|
| Heteromultimers with reduced or silenced effector function |
2016-10-03 |
2017-7-28 |
|
| Cytotoxic and anti-mitotic compounds, and methods of using the same |
2016-9-29 |
2017-4-06 |
|
| Methods For Determining Correlated Residues In A Protein Or Other Biopolymer … |
2016-7-27 |
2017-2-23 |
|
| Drug-conjugated bi-specific antigen-binding constructs |
2016-7-15 |
2021-10-19 |
2021-10-19 |
| Antibodies comprising c-terminal light chain polypeptide extensions and … |
2016-6-21 |
2016-8-31 |
|
| Multivalent heteromultimer scaffold design and constructs |
2016-1-20 |
2016-9-15 |
|
| Heteromultimer constructs of immunoglobulin heavy chains with mutations in the … |
2016-1-06 |
2016-9-08 |
|
| Bi-specific cd3 and cd19 antigen-binding constructs |
2015-1-15 |
2015-7-23 |
|
| Var2csa-drug conjugates |
2014-12-29 |
2017-6-14 |
|
| HER2 TARGETED BISPECIFIC ANTIGEN-BINDING CONSTRUCTS |
2014-11-27 |
2023-7-04 |
|
| Monovalent antigen binding constructs targeting egfr and/or her2 and uses … |
2014-11-13 |
2016-9-14 |
|
| Systems and methods for making two dimensional graphs of complex molecules |
2014-9-17 |
2022-8-23 |
2022-8-23 |
| Systems and methods for in silico evaluation of polymers |
2014-7-14 |
2022-2-01 |
2022-2-01 |
| Bispecific cd3 and cd19 antigen binding contructs |
2014-7-11 |
2016-3-14 |
|
| Systems and methods for physical parameter fitting on the basis of manual … |
2014-6-19 |
2016-12-22 |
|
| Modular protein drug conjugate therapeutic |
2014-5-23 |
2014-11-27 |
|
| Bispecific HER2 and HER3 antigen binding constructs |
2014-5-08 |
2019-3-26 |
2019-3-26 |
| Construtos de anticorpo que se ligam a 4-1bb e antígenos associados a tumor e … |
2019-10-10 |
2021-9-21 |
|
| Construtos de ligação a antígeno bispecíficos direcionados a her2 |
2014-11-27 |
2023-7-04 |
|